Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chi-Med Roll Continues With Positive Fruquintinib Phase III Data

Executive Summary

Chi-Med's China-focused strategy is paying off with positive Phase III top-line results for its home-grown VEGF inhibitor fruquintinib, keeping it on track to for a filing this year. But competition looms.


Related Content

New Drug Bonanza as Chi-Med, Eisai, Alexion Harvest Big Wins In China
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Chi-Med's Savolitinib: Overcoming Treatment Resistance in NSCLC
Pharma's First Quarter: Approvals, Successes and Setbacks
Big Pharma CEOs Descend On China: What’s The Likely Agenda?
AstraZeneca/Chi-Med Set For 'Selective' Pivotal Renal Cell Cancer Trial


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts